Boston Scientific Corporation reported net sales of $5.1 billion for the third quarter of 2025, an increase of 20.3% compared to $4.2 billion in the same period of 2024. The growth included a 15.3% rise in organic net sales and a 4.2 percentage point positive impact from acquisitions. For the nine months ended September 30, 2025, income before income taxes was $2.7 billion, with net income attributable to common stockholders at $2.2 billion, or $1.49 per share. The period included non-GAAP adjustments such as $669 million in amortization expense and $46 million in goodwill and intangible asset impairment charges. The company continued to focus on developing and marketing medical devices for a broad range of interventional specialties and highlighted the positive effects of recent acquisitions and foreign currency fluctuations on its financial results.